Jacob Waldrop - Sanara Medtech Chief Officer
| SMTI Stock | USD 35.91 0.71 1.94% |
Executive
Jacob Waldrop is Chief Officer of Sanara Medtech
| Address | 1200 Summit Avenue, Fort Worth, TX, United States, 76102 |
| Phone | 817 529 2300 |
| Web | https://sanaramedtech.com |
Sanara Medtech Management Efficiency
The company has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.18. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 47.2 M, while Non Currrent Assets Other are forecasted to increase to (18.1 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Centea | AngioDynamics | 45 | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Linda Cooper | Daxor | N/A | |
| Alisha Jerauld | Merit Medical Systems | N/A | |
| Jonathan Ngau | LeMaitre Vascular | 50 | |
| Suraj Satpathy | Envista Holdings Corp | N/A | |
| Rob Cannon | Repro Med Systems | N/A | |
| Mary Skafidas | AptarGroup | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
| Kathryn Kornafel | Daxor | N/A | |
| Claudia Ortiz | Envista Holdings Corp | N/A | |
| Daniel Ackerman | AptarGroup | 51 | |
| Addam Chupa | InfuSystems Holdings | 45 | |
| Kenneth Miller | Repro Med Systems | 55 | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Guido Manzo | Daxor | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| Paul Sumilas | Envista Holdings Corp | N/A | |
| Laura Piccinini | AngioDynamics | 55 | |
| Filippo Impieri | Envista Holdings Corp | N/A | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0508 |
Sanara Medtech Leadership Team
Elected by the shareholders, the Sanara Medtech's board of directors comprises two types of representatives: Sanara Medtech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanara. The board's role is to monitor Sanara Medtech's management team and ensure that shareholders' interests are well served. Sanara Medtech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanara Medtech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bill Fitzgerald, Compliance Officer | ||
| Jacob Waldrop, Chief Officer | ||
| Callon Nichols, Director Relations | ||
| Jane Fore, Chief Officer | ||
| Shawn Bowman, President Wound Care Division | ||
| Tricia Matteson, Director Marketing | ||
| Seth Yon, President Commercial | ||
| David Strasfeld, President Healing | ||
| Michael McNeil, CFO Secretary | ||
| Zachary Fleming, President Surgical Division | ||
| Tyler Palmer, Chief Officer | ||
| Carla Day, Director Services | ||
| Ronald Nixon, Executive Chairman of the Board | ||
| FACHM FAPWCA, Pres Services | ||
| Rebecca Mcmahon, President Development |
Sanara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanara Medtech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0508 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 335.75 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Insiders | 66.56 % | ||||
| Shares Owned By Institutions | 9.42 % | ||||
| Number Of Shares Shorted | 191.32 K | ||||
| Price To Book | 8.05 X |
Currently Active Assets on Macroaxis
When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.